We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARS icon
626
Tarsus Pharmaceuticals
TARS
$2.53B
– –
-10,034
Closed -$273K
TDC icon
627
Teradata
TDC
$2.88B
– –
-6,432
Closed -$222K
TDOC icon
628
Teladoc Health
TDOC
$1.66B
– –
-16,965
Closed -$166K
TFX icon
629
Teleflex
TFX
$5.93B
– –
-5,482
Closed -$1.15M
THC icon
630
Tenet Healthcare
THC
$22B
– –
-3,840
Closed -$511K
TLSI icon
631
TriSalus Life Sciences
TLSI
$271M
– –
-1
Closed -$6
TLSIW icon
632
TriSalus Life Sciences Warrant
TLSIW
$25.1M
– –
-333,333
Closed -$543K
TMDX icon
633
Transmedics
TMDX
$2.7B
– –
-9,298
Closed -$1.4M
TMUS icon
634
T-Mobile US
TMUS
$196B
– –
-4,337
Closed -$764K
TPL icon
635
Texas Pacific Land
TPL
$26.9B
– –
-2,391
Closed -$585K
TRN icon
636
Trinity Industries
TRN
$2.86B
– –
-10,376
Closed -$310K
TRV icon
637
Travelers Companies
TRV
$81B
– –
-1,794
Closed -$365K
TTC icon
638
Toro Company
TTC
$8.83B
– –
-12,853
Closed -$1.2M
TTI icon
639
TETRA Technologies
TTI
$1.1B
– –
-193,896
Closed -$671K
TXRH icon
640
Texas Roadhouse
TXRH
$13.7B
– –
-4,054
Closed -$696K
UCTT
641
Ultra Clean Holdings
UCTT
$3.21B
– –
-8,449
Closed -$414K
UHT
642
Universal Health Realty Income Trust
UHT
$625M
– –
-13,813
Closed -$541K
ULTA icon
643
Ulta Beauty
ULTA
$21.8B
– –
-2,191
Closed -$845K
UNH icon
644
UnitedHealth
UNH
$384B
– –
-490
Closed -$250K
UNM icon
645
Unum
UNM
$13.2B
– –
-11,057
Closed -$565K
UTZ icon
646
Utz Brands
UTZ
$1.25B
– –
-40,097
Closed -$667K
UVE icon
647
Universal Insurance Holdings
UVE
$1.25B
– –
-41,733
Closed -$783K
VC icon
648
Visteon
VC
$2.84B
– –
-1,996
Closed -$213K
VECO icon
649
Veeco
VECO
$2.7B
– –
-4,918
Closed -$230K
VERA icon
650
Vera Therapeutics
VERA
$2.37B
– –
-6,191
Closed -$224K
23 24 25
26
27

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.